Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

Mayo Clinic Proceedings
Paul RichardsonKenneth Anderson

Abstract

To determine the progression-free survival at 12 weeks, to evaluate the toxic effects, and to analyze the biological activity of thalidomide in patients with relapsed multiple myeloma (MM) after high-dose chemotherapy and stem cell transplantation. From 1999 to 2001, we performed a multicenter prospective phase 2 study in patients with MM that relapsed after high-dose chemotherapy and stem cell transplantation to evaluate the efficacy of oral thalidomide, with dose escalation from 200 to 600 mg/d over 12 weeks and a subsequent maintenance phase of 200 mg/d for up to 1 year. Outcome was correlated with serum and plasma levels of vascular endothelial growth factor and serum levels of tumor necrosis factor alpha, soluble intercellular adhesion molecule 1, interferon gamma, interleukin (IL) 2, and IL-6 during treatment. Thirty patients were treated (19 men and 11 women; median age, 58 years). The median number of prior therapies was 5, and the median duration from diagnosis of MM to study enrollment was 4.3 years. The 12-week progression-free survival rate was 67% (95% confidence interval [CI], 48%-86%). The observed response rate (partial response plus minor response) was 43% (95% CI, 28%-60%) with a median duration of 6 months. A...Continue Reading

Citations

Dec 13, 2006·TheScientificWorldJournal·Janice Jin HwangKenneth C Anderson
Nov 1, 2007·Clinical and Experimental Medicine·F MerchionneF Dammacco
Mar 26, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarJoan Bladé
Jun 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul G RichardsonAnthony A Amato
Nov 25, 2004·Hematology·Jean-Luc HarousseauPaul Richardson
Sep 8, 2011·Current Opinion in Neurology·Hadi Manji
Dec 2, 2004·Expert Opinion on Biological Therapy·Christine GalustianAngus G Dalgleish
Sep 13, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Teru HideshimaKenneth C Anderson
Nov 3, 2006·Nature Clinical Practice. Oncology·Paul G RichardsonKenneth C Anderson
Mar 8, 2008·Hematological Oncology·Jeannine Silberman, Sagar Lonial
Nov 6, 2009·American Journal of Clinical Oncology·Yuhong ZhouMichael Wang
May 25, 2010·European Journal of Haematology·Fortunato MorabitoAntonio Palumbo
Dec 26, 2012·Expert Opinion on Investigational Drugs·Neeraj Saini, Anuj Mahindra
Jan 5, 2006·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Geoff Saunders
Oct 14, 2005·Expert Review of Anticancer Therapy·Shaji Kumar, S Vincent Rajkumar
Aug 31, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Linda MileshkinH Miles Prince
Dec 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarUNKNOWN Eastern Cooperative Oncology Group
Jul 17, 2009·Pharmacological Reports : PR·Ilona Kaczmarczyk-SedlakHenryk I Trzeciak
Dec 17, 2009·The Cancer Journal·Diana CirsteaNoopur Raje
Oct 14, 2005·British Journal of Cancer·J B BartlettJ B Zeldis
Feb 5, 2008·Blood·Antonio PalumboJean-Luc Harousseau
Jul 9, 2008·Leukemia & Lymphoma·Donna E ReeceMichael J Kovacs
Feb 17, 2011·Expert Review of Hematology·Jacob P LaubachPaul G Richardson
Jul 14, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul Richardson, Kenneth Anderson
Sep 5, 2007·Bone Marrow Transplantation·M S RaabK C Anderson
Sep 28, 2007·Drugs & Aging·Hang QuachLinda Mileshkin
Sep 19, 2006·European Journal of Haematology·M Teresa CibeiraJoan Bladé
Aug 25, 2006·Clinical Journal of Oncology Nursing·Deborah S Doss
Feb 6, 2009·Leukemia & Lymphoma·Hang QuachH Miles Prince
Oct 1, 2011·Therapeutic Advances in Hematology·Waqas RehmanHillard M Lazarus
Oct 20, 2014·Journal of Neuro-oncology·Joost Louis Marie JongenPieter Sonneveld
Nov 26, 2014·Nature Reviews. Clinical Oncology·Meletios A DimopoulosKenneth C Anderson
Aug 8, 2015·Expert Opinion on Pharmacotherapy·Annemiek Broijl, Pieter Sonneveld

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis